# Viva Pharmaceutical Inc · 66-41 · CANADA — FDA import alert red lists: firms subject to detention without physical examination

For Viva Pharmaceutical Inc · 66-41 · CANADA, import alert is 66-41; import alert name is Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S; country is CANADA; product is Puralor Ci Tablets | Puralor Ci Tablets; product code is 54 Y - - 99 Vitamin, Mineral, Proteins and Unconventional Dietary Specialities For Humans and Animals, N.E.C. | 66 V - - 99 Miscellaneous Patent Medicines, Etc; date published is 05/10/2017; address is 13880 Viking Pl , Richmond, British Columbia CANADA, verified against its source on 2026-09-16.

- **Firm:** Viva Pharmaceutical Inc _(verified: appears in the quote below)_
- **Import alert:** 66-41
- **Import alert name:** Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.
- **Country:** CANADA _(verified: appears in the quote below)_
- **Address:** 13880 Viking Pl , Richmond, British Columbia CANADA _(verified: appears in the quote below)_
- **Date published:** 05/10/2017 _(verified: appears in the quote below)_
- **Product code:** 54 Y - - 99 Vitamin, Mineral, Proteins and Unconventional Dietary Specialities For Humans and Animals, N.E.C. | 66 V - - 99 Miscellaneous Patent Medicines, Etc. _(verified: each item appears in the quote below)_
- **Product:** Puralor Ci Tablets | Puralor Ci Tablets _(verified: each item appears in the quote below)_
- **FDA notes:** The product appears to be an unapproved new drug as the product labeling includes claims such as: 'Puralor Ci' is…formulated to improve the nutritional status of patients with anemias of nutritional origin – specifically folate malabsorption as determined by a licensed medical practitioner, and is associated with metabolic imbalances in transformylation biochemistry. Particular emphasis is on hyperhomocysteinemia – with or without a primary disease state…; Folate is effective in the treatment of hyperhomocysteinemia and/or megaloblastic anemias (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, childhood or other related folate-malabsorption, complications of an inborn or environmental origin…'. | The product appears to be an unapproved new drug as the product labeling includes claims such as: 'Puralor Ci' is…formulated to improve the nutritional status of patients with anemias of nutritional origin – specifically folate malabsorption as determined by a licensed medical practitioner, and is associated with metabolic imbalances in transformylation biochemistry. Particular emphasis is on hyperhomocysteinemia – with or without a primary disease state…; Folate is effective in the treatment of hyperhomocysteinemia and/or megaloblastic anemias (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, childhood or other related folate-malabsorption, complications of an inborn or environmental origin…'. _(verified: each item appears in the quote below)_

## What the source says

> Viva Pharmaceutical Inc Date Published : 05/10/2017 13880 Viking Pl , Richmond, British Columbia CANADA 54 Y - - 99 Vitamin, Mineral, Proteins and Unconventional Dietary Specialities For Humans and Animals, N.E.C. Date Published: 05/10/2017 Desc: Puralor Ci Tablets Notes: The product appears to be an unapproved new drug as the product labeling includes claims such as: 'Puralor Ci' is…formulated to improve the nutritional status of patients with anemias of nutritional origin – specifically folate malabsorption as determined by a licensed medical practitioner, and is associated with metabolic imbalances in transformylation biochemistry. Particular emphasis is on hyperhomocysteinemia – with or without a primary disease state…; Folate is effective in the treatment of hyperhomocysteinemia and/or megaloblastic anemias (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, childhood or other related folate-malabsorption, complications of an inborn or environmental origin…'. 66 V - - 99 Miscellaneous Patent Medicines, Etc. Date Published: 05/10/2017 Desc: Puralor Ci Tablets Notes: The product appears to be an unapproved new drug as the product labeling includes claims such as: 'Puralor Ci' is…formulated to improve the nutritional status of patients with anemias of nutritional origin – specifically folate malabsorption as determined by a licensed medical practitioner, and is associated with metabolic imbalances in transformylation biochemistry. Particular emphasis is on hyperhomocysteinemia – with or without a primary disease state…; Folate is effective in the treatment of hyperhomocysteinemia and/or megaloblastic anemias (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, childhood or other related folate-malabsorption, complications of an inborn or environmental origin…'.

## Source

- https://www.accessdata.fda.gov/cms_ia/importalert_190.html

Last verified: 2026-09-16. Review by: 2026-11-15.
Part of [FDA import alert red lists: firms subject to detention without physical examination](https://referencesource.org/fda-import-alert-red-list/).